Add Formweb to your mobile device
Approved Formulary
Search results for:
terazosin
terazosin
Brand names: Hytrin
| Form | Strength |
|---|---|
| CAPSULE, ORAL | 1 mg; 5 mg |
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | terazosin (Hytrin) |
| Criteria 1: Potentially inappropriate medication use in older adults. (Table 2) | |
| Drug(s) | non-selective peripheral alpha-1 blockers for the treatment of hypertension |
| Rationale | High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile. |
| Recommendation | Avoid use as an antihypertensive. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | non-selective peripheral alpha-1 blockers ⇄ Syncope |
| Rationale | Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension. |
| Recommendation | Avoid |
| Quality of evidence: High, Strength of Recommendation: Weak | |
| Drug(s) ⇆ disease or syndrome | non-selective peripheral alpha-1 blockers ⇄ Urinary incontinence (all types) in women |
| Rationale | Aggravation of incontinence. |
| Recommendation | Avoid in women. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | non-selective peripheral alpha-1 blockers ⇄ Loop diuretics |
| Risk Rationale | Increased risk of urinary incontinence in older women. |
| Recommendation | Avoid in older women, unless conditions warrant both drugs. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
Last updated: Sep. 19, 2025